Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy.

Abstract

Chronic granulomatous disease (CGD) is a rare inherited disorder due to loss-of-function mutations in genes encoding the NADPH oxidase subunits. Hematopoietic stem and progenitor cell (HSPC) gene therapy (GT) using regulated lentiviral vectors (LVs) has emerged as a promising therapeutic option for CGD patients. We performed non-clinical Good Laboratory Practice (GLP) and laboratory-grade studies to assess the safety and genotoxicity of LV targeting myeloid-specific Gp91phox expression in X-linked chronic granulomatous disease (XCGD) mice. We found persistence of gene-corrected cells for up to 1 year, restoration of Gp91phox expression and NADPH oxidase activity in XCGD phagocytes, and reduced tissue inflammation after LV-mediated HSPC GT. Although most of the mice showed no hematological or biochemical toxicity, a small subset of XCGD GT mice developed T cell lymphoblastic lymphoma (2.94%) and myeloid leukemia (5.88%). No hematological malignancies were identified in C57BL/6 mice transplanted with transduced XCGD HSPCs. Integration pattern analysis revealed an oligoclonal composition with rare dominant clones harboring vector insertions near oncogenes in mice with tumors. Collectively, our data support the long-term efficacy of LV-mediated HSPC GT in XCGD mice and provide a safety warning because the chronic inflammatory XCGD background may contribute to oncogenesis.

• Authors: Raisa Jofra Hernández, Andrea Calabria, Francesca Sanvito, Fabiola De Mattia, Giada Farinelli, Serena Scala, Ilaria Visigalli, Nicola Carriglio, Maura De Simone, Michela Vezzoli, Francesca Cecere, Maddalena Migliavacca, Luca Basso-Ricci, Maryam Omrani, Fabrizio Benedicenti, Rossana Norata, Paola Maria Vittoria Rancoita, Clelia Di Serio, Paola Albertini, Patrizia Cristofori, Luigi Naldini, Bernhard Gentner, Eugenio Montini, Alessandro Aiuti, Alessandra Mortellaro
• Journal: Molecular therapy : the journal of the American Society of Gene Therapy (Mol Ther) Vol. 29 Issue 1 Pg. 86-102 (01 06 2021) ISSN: 1525-0024 [Electronic] United States
• PMID: 33010230 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Chemical References

• NADPH Oxidase 2

Topics

• Animals
• Disease Models, Animal
• Genetic Therapy (adverse effects, methods)
• Genetic Vectors (administration & dosage, genetics)
• Granulomatous Disease, Chronic (complications, genetics, therapy)
• Hematologic Neoplasms (etiology)
• Humans
• Lentivirus (genetics)
• Mice
• NADPH Oxidase 2 (genetics, metabolism)
• Time Factors
• Treatment Outcome